Posted 4/10/2024, 8:25:57 PM
U.S. Accuses Regeneron of Fraudulently Inflating Medicare Drug Prices for Eylea
- U.S. files complaint against Regeneron Pharmaceuticals for allegedly reporting fraudulent drug prices to Medicare for the drug Eylea
- Regeneron allegedly failed to properly report credit card processing fees paid to benefit customers as price concessions, resulting in inflated Medicare reimbursements
- Hundreds of millions of dollars in alleged inflated reimbursements by Medicare due to Regeneron's actions
- Complaint prompted by whistleblower lawsuit filed under False Claims Act qui tam provisions
- If found liable, Regeneron faces treble damages plus penalties under the False Claims Act
